Recent progress in antiretrovirals - lessons from resistance

被引：35

作者：

Adamson, Catherine S. ^{[1
]}

Freed, Eric O. ^{[1
]}

机构：

[1] NCI, Virus Cell Interact Sect, HIV Drug Resistance Program, Frederick, MD 21702 USA

来源：

DRUG DISCOVERY TODAY | 2008年 / 13卷 / 9-10期

关键词：

D O I：

10.1016/j.drudis.2008.02.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Recent failures in efforts to develop an effective vaccine against HIV-1 infection have emphasized the importance of antiretroviral therapy in treating HIV-1-infected patients. Thus far, inhibitors of two viral enzymes, reverse transcriptase and protease, have had a profoundly positive impact on the survival of HIV-1-infected patients. However, new inhibitors that act at diverse steps in the viral replication cycle are urgently needed because of the development of resistance to currently available antiretrovirals. This review summarizes recent progress in antiretroviral drug discovery and development by specifically focusing on novel inhibitors of three phases of replication: viral entry, integration of the viral DNA into the host cell genome and virus particle maturation.

引用

页码：424 / 432

页数：9

共 94 条

[41] Biology of CCR5 and its role in HIV infection and treatment [J].

Lederman, Michael M. ;

Penn-Nicholson, Adam ;

Cho, Michael ;

Mosier, Donald .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (07) :815-826

[42] PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing [J].

Li, F ;

Goila-Gaur, R ;

Salzwedel, K ;

Kilgore, NR ;

Reddick, M ;

Matallana, C ;

Castillo, A ;

Zoumplis, D ;

Martin, DE ;

Orenstein, JM ;

Allaway, GP ;

Freed, EO ;

Wild, CT .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (23) :13555-13560

[43] HIV entry inhibitors targeting gp41: From polypeptides to small-molecule compounds [J].

Liu, Shuwen ;

Wu, Shuguang ;

Jiang, Shibo .

CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (02) :143-162

[44]

MALET ID, 2007, C ANT THER BARD, V12, pS9

[45] Latency: the hidden HIV-1 challenge [J].

Marcello, Alessandro .

RETROVIROLOGY, 2006, 3 (1)

[46] Metal-dependent inhibition of HIV-1 integrase by β-diketo acids and resistance of the soluble double-mutant (F185K/C280S) [J].

Marchand, C ;

Johnson, AA ;

Karki, RG ;

Pais, GCG ;

Zhang, XC ;

Cowansage, K ;

Patel, TA ;

Nicklaus, MC ;

Burke, TR ;

Pommier, Y .

MOLECULAR PHARMACOLOGY, 2003, 64 (03) :600-609

[47] Rapid and durable Antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection - Results of a 48-week controlled study [J].

Markowitz, Martin ;

Nguyen, Bach-Yen ;

Gotuzzo, Eduardo ;

Mendo, Fernando ;

Ratanasuwan, Winai ;

Kovacs, Colin ;

Prada, Guillermo ;

Morales-Ramirez, Javier O. ;

Crumpacker, Clyde S. ;

Isaacs, Robin D. ;

Gilde, Lucinda R. ;

Wan, Hong ;

Miller, Michael D. ;

Wenning, Larissa A. ;

Teppler, Hedy .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 46 (02) :125-133

[48] Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals [J].

Markowitz, Martin ;

Morales-Ramirez, Javier O. ;

Nguyen, Bach-Yen ;

Kovacs, Colin M. ;

Steigbigel, Roy T. ;

Cooper, David A. ;

Liporace, Ralph ;

Schwartz, Robert ;

Isaacs, Robin ;

Gilde, Lucinda R. ;

Penning, Larissa ;

Zhao, Jing ;

Teppler, Hedy .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) :509-515

[49] Generation and properties of a human immunodeficiency virus type I isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D) [J].

Marozsan, AJ ;

Kuhmann, SE ;

Morgan, T ;

Herrera, C ;

Rivera-Troche, E ;

Xu, S ;

Baroudy, BM ;

Strizki, J ;

Moore, JP .

VIROLOGY, 2005, 338 (01) :182-199

[50]

MCCOLL DF, 2007, C ANT THER BARB, V12, pS11

← 1 2 3 4 5 6 7 8 9 10 →